Amgen has made about $5 billion in direct capital investments in the US since the Tax Cuts and Jobs Act of 2017 was passed.
Amgen
IMDELLTRA’s safety profile was consistent with the recognized profile. Detailed DeLLphi-304 results will be presented at an upcoming medical congress.
The trial achieved its primary endpoint, as previously revealed at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting.
